Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eleclazine in symptomatic hypertrophic cardiomyopathy
NCT02291237Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of eleclazine in hypertrophic cardiomyopathy (HCM), sponsored by Gilead Sciences. Started Feb 2015; status: terminated.
02
Drugs
eleclazine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT02291237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291237.